Quantity limits govern coverage amounts

Quantity limits listed in the Premium formulary define the amount of a drug that will be covered (e.g., tablets per day, mL per day, per‑fill or per period). When a medication includes a quantity limit, coverage is limited to the specified amount and timeframe; quantities above the listed limit may not be covered and could require payer review.

• Coverage limited to the specified per‑day, per‑fill, or time‑period quantity as shown in the formulary table.
• If quantities exceed the listed limit, coverage may be denied or prior authorization may be required.

Quantity limits govern coverage

Coverage is managed primarily by preset quantity limits rather than explicit prior‑authorization conditions in this section; follow the formulary’s stated per‑day and per‑fill limits when prescribing.

• Quantity limits specify daily tablets or mL and short‑course durations (commonly up to 7 days for new opioid starts).
• When differences exist between this list and a member’s benefit plan, the benefit plan documents govern.

Quantity limits based on opioid treatment experience

Opioid quantity limits differ depending on whether the patient is new to opioid treatment or experienced; new‑to‑treatment patients are subject to lower per‑day quantities and shorter course durations (commonly up to 7 days).

• Examples: hydromorphone liquid (1 mg/mL) — 10 mL/day for new patients vs 18 mL/day for experienced patients.
• Hydromorphone suppository 3 mg — 3 supps/day (new) vs 6 supps/day (experienced).

Quantity limits may trigger prior authorization

Quantity limits are defined by formulation and patient opioid‑experience status; prescriptions exceeding the stated limits may require prior authorization per payer processes.

• Standard non‑specialty per‑day limits (liquid, suppository, tablet) are listed; prior authorization may be required for amounts above those limits.
• Some items (starter/titration packs) imply special handling when supplies differ from standard limits.

Prior authorization for quantities above limits

If a prescription exceeds the formulary quantity listed for a medication or for the patient’s opioid‑experience category, submit a prior authorization with supporting documentation (medical necessity) as required by the payer.

• Follow payer prior authorization processes when requesting quantities above the formulary limit.
• Maintain documentation of medical necessity for override or prior‑authorization requests.

Quantity limits enforcement

The formulary presents enforced quantity limits by formulation and patient status; prescribers must ensure prescriptions conform to the listed per‑day and per‑course limits to avoid adjudication issues.

• Pharmacy adjudication will reference the formulary per‑fill and period limits when determining allowed dispense quantity.
• Amounts above the listed limits may be reduced at point of adjudication or denied.

Prior authorization for quantities above limits

Requests for quantities above the listed daily or course limits for opioid formulations may be subject to prior authorization review; providers should expect review when exceeding the stated per‑day limits for the patient’s experience status.

• Quantity limits are applied per formulation (e.g., hydromorphone tabs, suppositories, liquid) and differ for new vs experienced patients.
• Prior authorization may be required if prescribing beyond the listed per‑day amounts or the up‑to‑7‑day initial supply.

Quantity limits vary by patient opioid experience

Prescribers must follow per‑product quantity limits that vary by whether the member is new to opioid treatment or experienced; determine and apply the appropriate limit for each product when submitting claims or prior‑auth requests.

• Limits differ by product and formulation (e.g., hydromorphone tabs/supps/liquid have separate limits).
• Use the patient’s opioid‑treatment status to select the applicable per‑day limit.

Prior authorization for quantities above limits

When prescribing amounts above the formulary’s daily limits for listed products, anticipate that a prior authorization may be required and that the request must document the rationale and medical necessity.

• Some liquid formulations and tablet strengths list higher experienced‑user limits; requests above those listed amounts may require PA.
• The formulary and its limits are effective July 1, 2026; follow payer PA procedures for exceptions.

Quantity limits — prior authorization may be required

Quantity limits are specified per medication (examples include opioid limits expressed as tablets per day or mL per day and short‑course caps up to 7 days); prescribers seeking quantities above these limits may need to submit a prior authorization per payer process.

• Examples: many opioids limited by tabs/day for up to 7 days; other agents have per‑28/30/365‑day limits shown in the formulary.
• If a requested quantity exceeds the listed limit, follow the prior‑authorization process and supply documentation.

Prior authorization implication

Some products (e.g., starter packs or titration packs) imply special handling; prior authorization or additional review may be required when supplies differ from standard quantity limits.

• Examples in the document reference starter or titration packs that may require special consideration.
• Contact payer or follow PA guidance if prescribing starter/titration packs outside standard limits.

Prior authorization for quantities above limits

Some requests above the stated quantity limits may require prior authorization per payer process; the formulary limits are effective July 1, 2026 and the list is subject to updates.

• Claims exceeding listed quantity limits may be subject to denial or prior authorization review.
• The formulary is regularly updated; verify current limits when submitting requests.

Step therapy (not specified)

Quantity limit rules are established using FDA‑approved indications, medication labeling, and accepted clinical recommendations; the formulary does not define a step‑therapy sequence in this section.

• Quantity limits are based on FDA uses, label instructions, and clinical guidance.
• No explicit step‑therapy sequences are specified in this extract.

Step therapy not specified

No step‑therapy sequences are provided in this fragment; the policy focuses on numeric quantity limits and on determining whether a patient is 'new to opioid treatment' or 'experienced' as part of applying those limits.

• Determination of 'new' vs 'experienced' opioid treatment functions as a step when applying quantity limits.
• Providers should not assume step‑therapy requirements from this extract; follow separate step‑therapy policy documents if applicable.

Coverage limited to listed quantity

If a medication includes a quantity limit, only the specified amount will be covered; members should contact their provider or the phone number on their ID card for questions.

• Coverage is limited to the listed quantity limits; amounts above the listed limits may not be covered.
• Members should consult their benefit documents or contact the payer for questions.

Document patient opioid treatment status

Prescriptions must indicate whether the patient is new to opioid treatment or experienced so the correct per‑day limit and allowable short‑course duration (commonly up to 7 days for new starts) are applied.

• Document opioid‑treatment status on the prescription or accompanying prior‑auth request.
• New‑to‑treatment examples: lower per‑day limits and up to 7 days maximum supply.

Document whether the patient is new to opioid treatment or experienced

Prescribers should document the patient’s opioid‑treatment status (new vs experienced), the prescribed formulation, and the daily volume/number to justify that the requested quantity falls within policy limits or to support an override/PA request.

• Include formulation (liquid/tablet/suppository), concentration or strength, and intended daily dose and duration when submitting claims or PA.
• Maintain supporting clinical documentation when requesting quantities above listed limits.

Patient experience status required

Prescriptions should indicate patient opioid‑experience status because different per‑day limits apply (examples: hydromorphone liquid 10 mL/day for new vs 18 mL/day for experienced; suppositories 3 vs 6 per day).

• Ensure prescriptions include the patient status so the pharmacy can apply the appropriate limit at adjudication.
• Differentiate prescribing for new vs experienced opioid treatment to align with formulary limits.

Prescriber should document opioid treatment status

Prescribers should document opioid‑treatment status (new vs experienced) on prescriptions to determine applicable daily limits and allowable duration (initial prescriptions for new patients are commonly limited to up to 7 days).

• Documentation supports correct adjudication and avoids denials for exceeding formulary limits.
• If exceeding the limit, include medical necessity documentation with any PA request.

Document patient opioid experience

Prescriptions should state whether the patient is new to opioid treatment or experienced, because limits differ by status and formulation; this information is used by pharmacy adjudication to apply the correct per‑day limit.

• Include new vs experienced status when submitting claims to ensure correct per‑day limit is applied.
• Limits for new patients typically include both lower per‑day counts and a short‑course cap (up to 7 days).

Documentation of treatment status

Providers must adhere to the formulary’s daily tablet or liquid limits for new versus experienced opioid patients; documentation distinguishing status may be required by the plan to support coverage for the requested quantity.

• Follow the listed per‑product daily limits (examples: PROLATE tabs limits and liquid mL/day values) based on patient status.
• When requesting >listed limits, supply rationale and supporting documentation for PA.

Match prescription to listed quantity limit

Present prescriptions with dosing and intended duration consistent with the stated per‑day and per‑fill limits (for example, short opioid prescriptions are commonly limited to up to 7 days for new starts).

• Match dispense quantity to the per‑day limit and intended days’ supply to avoid denials or reductions at adjudication.
• If a larger supply is clinically indicated, prepare documentation to support a PA or override request.

Documentation for dispensing

Pharmacies will adjudicate claims against the formulary per‑fill and period quantity limits; providers should ensure the dispense request matches those limits or submit a prior authorization with supporting documentation.

• Pharmacy adjudication may reduce or deny quantities above the listed limits at point of sale.
• Include formulation, daily dose, and intended duration to facilitate correct dispensing.

Documentation for override requests

When requesting quantities above the listed limits, maintain documentation supporting medical necessity and include it with the prior authorization or appeal as required by the payer; the formulary is subject to updates.

• Keep clinical records explaining why the higher quantity is necessary for the patient.
• Provide detailed dosing, duration, prior treatment history, and any relevant clinical notes with PA requests.

Coverage is limited to the listed quantity limits

Coverage is limited to the listed quantity limits; amounts above the listed limits may not be covered and could be denied or reduced during claims adjudication.

• If a medication includes a quantity limit, only the specified amount will be covered.
• Claims exceeding the published limits are subject to denial or reduced quantity at point of adjudication.

Quantity exceedance may trigger denial

Prescriptions that exceed the listed per‑day or duration limits (for example, exceeding the new‑patient or experienced‑patient per‑day tablet or mL limits or supplies longer than the stated short‑course durations) may be denied.

• Examples: hydromorphone limits (liquid/supps/tabs) and many opioids restricted to up to 7 days for new starts.
• Requests above listed per‑day amounts (e.g., >10 mL/day for new liquids, >18 mL/day for experienced liquids, >3 supps/day for new users) risk denial.

Patient opioid‑treatment status must be documented

Prescriptions should indicate whether the patient is new to opioid treatment or experienced so adjudicators can apply the appropriate per‑day limit and short‑course policy; failure to document status may lead to application of the lower (new‑patient) limits or denial.

• Document status on the prescription or include it in the PA request to ensure correct application of limits.
• If status is unclear, the plan may apply the more restrictive new‑patient limits.